Evidence map›Paper›PMID 30867005›Full record

ArticleBreast cancer research : BCR2019

Impact of obesity on breast cancer recurrence and minimal residual disease.

Brett L Ecker, Jun Y Lee, Christopher J Sterner, Aaron C Solomon, Dhruv K Pant, Fei Shen, Javier Peraza, Lauren Vaught, Samyukta Mahendra, George K Belka and 3 more

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 82 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Escape from breast tumor dormancy: The convergence of obesity and menopause.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Brett L EckerDepartment of Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Jun Y LeeDepartment of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Christopher J SternerDepartment of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Aaron C SolomonDepartment of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Dhruv K PantDepartment of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Fei ShenDepartment of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Javier PerazaDepartment of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Lauren VaughtDepartment of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Samyukta MahendraDepartment of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
George K BelkaDepartment of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Tien-Chi PanDepartment of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Kathryn H SchmitzPenn State Cancer Institute, Penn State College of Medicine, Hershey, PA, 17033, USA.
Lewis A ChodoshDepartment of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. chodosh@pennmedicine.upenn.edu.
University of Pennsylvania · USPenn State Milton S. Hershey Medical Center · US

Funding

The Women In Steady Exercise Research (WISER) SurwVor TrialU54CA155850 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SAWER, DAVID · 2011 to 2015
$9.1M
In Vivo Ras-induced Senescence and TumorigenesisR01CA098371 · NCI · UNIVERSITY OF PENNSYLVANIA · PI LEWIS A CHODOSH · 2003 to 2026
$7.4M
Minimal Residual Disease and Mechanisms of Breast Cancer RecurrenceR01CA143296 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHODOSH, LEWIS A · 2010 to 2022
$3.5M
Survival and Recurrence of Dormant Cancer CellsR01CA148774 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHODOSH, LEWIS A · 2010 to 2022
$3.4M
Secondary Prevention through Surveillance and InterventionR01CA208273 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHODOSH, LEWIS A, DEMICHELE, ANGELA · 2017 to 2021
$3.2M
NCI NIH HHS R01 CA098371NCI NIH HHS R01 CA143296NCI NIH HHS R01 CA148774NCI NIH HHS R01 CA208273NCI NIH HHS U54 CA155850
6 · The paper itself

Abstract

backgroundObesity is associated with an increased risk of breast cancer recurrence and cancer death. Recurrent cancers arise from the pool of residual tumor cells, or minimal residual disease (MRD), that survives primary treatment and persists in the host. Whether the association of obesity with recurrence risk is causal is unknown, and the impact of obesity on MRD and breast cancer recurrence has not been reported in humans or in animal models.

methodsDoxycycline-inducible primary mammary tumors were generated in intact MMTV-rtTA;TetO-HER2/neu (MTB/TAN) mice or orthotopic recipients fed a high-fat diet (HFD; 60% kcal from fat) or a control low-fat diet (LFD; 10% kcal from fat). Following oncogene downregulation and tumor regression, mice were followed for clinical recurrence. Body weight was measured twice weekly and used to segregate HFD mice into obese (i.e., responders) and lean (i.e., nonresponders) study arms, and obesity was correlated with body fat percentage, glucose tolerance (measured using intraperitoneal glucose tolerance tests), serum biomarkers (measured by enzyme-linked immunosorbent assay), and tissue transcriptomics (assessed by RNA sequencing). MRD was quantified by droplet digital PCR.

resultsHFD-Obese mice weighed significantly more than HFD-Lean and LFD control mice (p < 0.001) and had increased body fat percentage (p < 0.001). Obese mice exhibited fasting hyperglycemia, hyperinsulinemia, and impaired glucose tolerance, as well as decreased serum levels of adiponectin and increased levels of leptin, resistin, and insulin-like growth factor 1. Tumor recurrence was accelerated in HFD-Obese mice compared with HFD-Lean and LFD control mice (median relapse-free survival 53.0 days vs. 87.0 days vs. 80.0 days, log-rank p < 0.001; HFD-Obese compared with HFD-Lean HR 2.52, 95% CI 1.52-4.16; HFD-Obese compared with LFD HR 2.27, 95% CI 1.42-3.63). HFD-Obese mice harbored a significantly greater number of residual tumor cells than HFD-Lean and LFD mice (12,550 ± 991 vs. 7339 ± 2182 vs. 4793 ± 1618 cells, p < 0.001).

conclusionThese studies provide a genetically engineered mouse model for study of the association of diet-induced obesity with breast cancer recurrence. They demonstrate that this model recapitulates physiological changes characteristic of obese patients, establish that the association between obesity and recurrence risk is causal in nature, and suggest that obesity is associated with the increased survival and persistence of residual tumor cells.

Indexed as

AnimalsBody Mass IndexBody WeightBreast NeoplasmsCell Line, TumorDatasets as TopicDiet, High-FatDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleHumansMammary Neoplasms, ExperimentalMice, ObeseMice, TransgenicNeoplasm Recurrence, LocalNeoplasm, ResidualERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBreast cancerHigh-fat dietObesityRecurrenceTumor dormancy

Identifiers

PMID30867005
PMCPMC6416940
OpenAlexW2923001939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.